Tradestie Institutional Equity Comparison Engine

IBO vs PLRZ โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

IBO Overall Edge

IBO Captures Institutional Edge (2โ€“1 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Impact BioMedical, Inc. (IBO) driven by superior Valuation, Growth & Margin while PLRZ counters with relative strength in Momentum & Technical. Fundamentally, IBO trades at N/M Forward P/E with -12621.0% operating margin (+16.7% YoY revenue) versus PLRZ at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, IBO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against PLRZ sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner IBO
IBO N/M vs PLRZ N/M Fwd P/E
Growth & Margin Winner IBO
Op Margin -12621.0% vs 0.0% ยท YoY +16.7% vs +0.0%
Momentum & Technical Winner PLRZ
1Y +872.5% vs +1314.3% ยท 52W Pos 68% vs 59%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
IBO NYSE American
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.96
-3.5% 1D
Market Cap $41.2M
1M Return +85.07%
1Y Return +872.55%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0
PLRZ NASDAQ
Polyrizon Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$10.89
-1.45% 1D
Market Cap $27.9M
1M Return +8.9%
1Y Return +1314.29%
Forward P/E N/M
Unified AI Score
31.6 / 100 SELL
Tech 17.0 Fund 33.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IBO +872.55% PLRZ +1314.29% Spread: +441.74 pp (PLRZ Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
IBO TTM Op. Margin: -12621.0% PLRZ TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBO vs PLRZ. Trailing 12-month operating profitability (IBO -12621.0% vs PLRZ 0.0%) and valuation multiples (IBO N/M vs PLRZ N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IBO (7) vs PLRZ (2)
Institutional Metric IBO PLRZ Criterion Row Winner
Market Capitalization Scale $41.2M $27.9M Larger Scale IBO
Trailing P/E Ratio Valuation 0.4x N/M Lower Multiple IBO
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +16.7% +0.0% Higher Growth IBO
Operating Margin (TTM) Profitability -12621.0% 0.0% Higher Margin PLRZ
Net Profit Margin Profitability 4247.4% 0.0% Higher Margin IBO
Return on Equity (ROE) Capital Efficiency 71.2% -21.4% Higher ROE IBO
52-Week Range Position Momentum 68% ($0โ€“$7) 59% ($0โ€“$18) Stronger Trend IBO
Beta / 30D Volatility Risk Regime -6.75ฮฒ ยท 120% Vol -0.03ฮฒ ยท 88% Vol Lower Realized Risk PLRZ
Unified Institutional Score Composite Signal 36.8 / 100 (SELL) 31.6 / 100 (SELL) Higher Composite IBO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IBO vs PLRZ Buy Guide
IBO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live IBO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PLRZ UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live PLRZ Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IBO nor PLRZ registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.